

**AMENDMENTS TO THE CLAIMS**

*Please amend claims as follows:*

Claims 1-8. (Canceled).

9. **(Currently Amended)** A method for preparing an organ by perfusion prior to transplantation or storage of the organ comprising:

(I) providing an ischemic reperfusion injury prevention preparation for perfusion of an organ prior to transplantation or storage of the organ, wherein the ischemic reperfusion injury prevention preparation comprises:

(A) a soluble derivative of a soluble polypeptide, wherein the soluble derivative ~~comprises~~ **consists of**:

~~[[1]]~~ a fragment of complement receptor 1 (CR1), wherein the CR1 fragment consists of first three Short Consensus Repeats (SCR1-3), and has a complement inhibitory activity, wherein the fragment is conjugated to myristoyl and a basic amino acid sequence, according to ~~has a sequence that is set forth in SEQ ID NO: 1 and has an complement inhibitory activity, and~~

~~(2) at least two membrane binding elements, wherein (a) at least one membrane binding element is a non-peptidic membrane binding element comprising acyl groups, and (b) at least one membrane binding element is a peptidic membrane binding element comprising basic amino acids, wherein the peptidic membrane binding element is bound to the non-peptidic membrane binding element and the fragment of complement receptor 1; and~~

(B) a physiologically acceptable and non-reducing flush storage solution, wherein the physiologically acceptable flush storage solution is SOLTRAN, which is a kidney perfusion solution;

and

(II) perfusing the organ with the ischemic reperfusion injury prevention preparation, wherein the organ contains the ischemic reperfusion injury prevention preparation while isolated and prior to implantation.

**Claims 10-15. (Canceled).**

16. **(Currently Amended)** The method according to claim 9, wherein the fragment of complement receptor 1 (CR1) **consists of first three Short Consensus Repeats (SCR1-3) and** has **[[a]] the** sequence according to positions 2 to 197 of SEQ ID NO.1.

**Claims 17-18. (Canceled).**

19. (Previously presented) The method according to claim 9, wherein the organ is a kidney, a heart, a liver, or a lung.

20. (Previously presented) The method according to claim 19, wherein the organ is a human organ.

21. (Previously presented) The method according to claim 19, wherein the organ is a non-human animal organ.

**Claims 22-24. (Canceled).**